Experimental human challenge infections can accelerate clinical malaria vaccine development.
about
Systems immunology of human malariaVaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infectionProfiling the host response to malaria vaccination and malaria challengeMalaria vaccine: a future hope to curtail the global malaria burdenCorrelates of Protection for M Protein-Based Vaccines against Group A StreptococcusLinking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.Young lives lost as B cells falter: what we are learning about antibody responses in malaria.Plasmodium vivax Controlled Human Malaria Infection - Progress and ProspectsMalaria modeling: In vitro stem cells vs in vivo modelsGut microbiota elicits a protective immune response against malaria transmissionExternal quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillanceComparison of clinical and parasitological data from controlled human malaria infection trialsAdherence to chemoprophylaxis and Plasmodium falciparum anti-circumsporozoite seroconversion in a prospective cohort study of Dutch short-term travelers.Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers.Measurement of parasitological data by quantitative real-time PCR from controlled human malaria infection trials at the Walter Reed Army Institute of Research.Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialCurrent advances in humanized mouse models.High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical MalariaMalaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease.Differential adhesive properties of sequestered asexual and sexual stages of Plasmodium falciparum on human endothelial cells are tissue independentThe blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsCytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites.Vaccines against malaria-still a long way to go.TB Vaccines: The (Human) Challenge Ahead.Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionOptimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe.Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection.Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studiesEvaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres.Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection.Impact of acute malaria on pre-existing antibodies to viral and vaccine antigens in mice and humansLessons learnt from the first controlled human malaria infection study conducted in Nairobi, KenyaNitric oxide is involved in the upregulation of IFN-γ and IL-10 mRNA expression by CD8⁺ T cells during the blood stages of P. chabaudi AS infection in CBA/Ca miceLongevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humansMosquitoes Reset Malaria ParasitesAntiplasmodial activity of bacilosarcin A isolated from the octocoral-associated bacterium Bacillus sp. collected in PanamaControlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity ratesVaccinology in the era of high-throughput biology.
P2860
Q21032488-6218A6C8-67CA-4E0E-8D09-B23739CC02D6Q24628167-47B83C3B-7D01-490C-A33A-68D89E1D238BQ26800494-60820C1C-10DC-4BF9-AB0A-8831AD157120Q26996425-8B77E2F7-B761-442B-A0B7-F2B0A1A6FD37Q27009175-A753F314-B7DA-438B-819D-8AB0DB283C7CQ27324132-1DE53635-397E-49FA-BCD2-A6A3C22EAEDAQ27687235-94D29AEA-8570-419A-9865-6129057B8DC2Q28066456-8C176502-4ECF-465F-BDC3-4E08ED2D6BD0Q28071293-A65D148B-5063-488E-A1FC-039B5B4E9D52Q28253398-41126F54-722B-4FD1-9A51-3D60EBA397DDQ28538917-C93DC9E4-E60D-48C2-8AC1-3C54B7E8625DQ28728616-27DE7866-3035-4B56-9300-D797DA309E6CQ29353761-B0BCA69D-BFA8-4FE8-862E-08AFC991A7A5Q30403003-F1DDA338-B5D1-4A29-8E4E-045DBD4E0DC1Q30838965-990DA8DD-4234-48FF-BB40-858FA6CE8925Q30991737-BCBFE4EC-99F6-47E4-850F-554EA30A27DBQ33577361-4630BDEA-3317-4AE8-8326-55FD04AA55EEQ33646573-F70D0BD3-5AA8-45BB-8DA3-7D0585FB5BD0Q33821137-922FD2A5-117A-4B43-B442-8D394833007AQ34171103-D0DCBC3C-A3A8-40D1-B529-8E0DCAE977C5Q34241973-43AAA25D-2EF5-4BE2-A9DC-88FED3B3E165Q34301461-7E2F591E-687C-49C5-8341-D95FFFE269CEQ34399831-0BEB831C-4914-46E0-9B88-C40981AF2EB5Q34556687-21824AB5-0F2F-49A4-8617-9029EE90DA31Q34676075-7FB7A4F5-9C54-48B9-8AB5-917BF6ACCF80Q34687174-21348C72-7FEB-4E87-B125-61447F10A840Q34792326-E3B3F3B4-FEBC-4835-A488-4D69E3EF234BQ34852105-D5813587-39E9-4955-ADEF-7B2E27C7FC4BQ35052801-4F4C57E4-549C-4F54-94CE-24FCE047CBA8Q35163318-83C4242B-EB25-493F-A527-669BE100306DQ35211679-C08FBE5A-5692-4F87-863C-3C79247A8FA2Q35439859-8AA26664-74DF-4384-BFF4-B876C19BDEC7Q35547272-6D9EC233-0224-4E41-AEC3-1EAAC52788C1Q35559418-C638D643-8F26-4379-B06C-35B80C34CD76Q35566860-A138396F-D12E-4E82-9F69-DD3EACC569F0Q35586865-B1C5C817-51DB-425E-A7DB-B9114F181B54Q35680345-84E8A524-0AF5-490F-B24E-6978D88599B1Q35770465-760DA658-E4BB-4995-B05B-D5898246B369Q35922955-06D5C9AB-CB35-4417-9BA9-20B1E6EEB825Q35923851-C3E8C774-C555-4B1E-BF2F-F9B4F650DF9B
P2860
Experimental human challenge infections can accelerate clinical malaria vaccine development.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Experimental human challenge i ...... l malaria vaccine development.
@en
Experimental human challenge i ...... l malaria vaccine development.
@nl
type
label
Experimental human challenge i ...... l malaria vaccine development.
@en
Experimental human challenge i ...... l malaria vaccine development.
@nl
prefLabel
Experimental human challenge i ...... l malaria vaccine development.
@en
Experimental human challenge i ...... l malaria vaccine development.
@nl
P356
P1476
Experimental human challenge i ...... l malaria vaccine development.
@en
P2093
Meta Roestenberg
Vasee S Moorthy
P2860
P356
10.1038/NRI2902
P577
2011-01-01T00:00:00Z